• 沒有找到結果。

與肝細胞再生有關之生長因子接受體在肝細胞癌的表現

N/A
N/A
Protected

Academic year: 2021

Share "與肝細胞再生有關之生長因子接受體在肝細胞癌的表現"

Copied!
3
0
0

加載中.... (立即查看全文)

全文

(1)

1

行政院國家科學委員會專題研究計畫成果報告

與肝再生有關之生長因子受體在肝細胞癌之表現

Expr ession of r eceptor s of gr owth

factor s r elated to liver

r egener ation in hepatocellular

car cinoma

計畫編號:NSC

88-2314-B-002-192-執行期限:87 年 8 月 1 日至 88 年 7 月 31 日

主持人:李嘉哲

臺大醫學院內科 一、中文摘要 高再發率以及低長期存活率一直是肝 細胞癌臨床上面臨的問題。肝局部切除 後,肝細胞生長因子、介白質 6、轉形生長 因子、表皮生長因子促成肝的再生。我們 檢驗了 40 例手術切除之肝細胞癌的標本, 測定上述生長因子的受體是否在肝細胞癌 有表現以及它們的表現是否與肝細胞癌的 再發有關。我們發現大部分的肝細胞癌都 有表現上述生長因子的受體。受體的量與 癌大小無關。肝細胞的再發與受體的量, 肝硬化的有無,病人年齡、性別, HBsAg 及 Anti-HCV 無關。在 71%病人,介白質 6 受體在正常肝細胞與肝細胞癌大小不同。 總結為肝細胞癌有表現與肝再生有生長關 因子之受體。肝細胞癌再發與受體之表現 無關。肝細胞癌生長之主要控制機轉可能 與肝再生控制機轉不同。 關鍵詞:肝細胞癌、肝細胞生長因子、介 白質 6、表皮生長因子、 受體 Abstr act

high recurrence rate and poor long term survival of patients with hepatocellular carcinoma (HCC) receiving operation remains a serious clinical problem. After partial hepatectomy, hepatocyte growth factor,

interlukin-6, transforming growth factor and epidermal growth factor contribute to the regeneration of liver. We examined 40 surgical resected HCC samples to determin whether the receptors of above growth factors were expressed in HCC and how they correlated with tumor recurrence. We found that most of the HCC did express receptors for growth factors. The amount of receptors did not correlate with the tumor size. The recurrence of HCC did not correlate with the amount of receptors in tumor tissue, age, sex, HBsAg, Anti-HCV and presence of liver cirrhosis. There is size difference of interleukin 6 receptor between nontumor and tumor tissue in 71% cases. In conclusion, HCC expresses receptors for growth factors related to liver regeneration. The recurrence of HCC did not related to expression of growth factor receptors. The growth of HCC is probably mainly controlled by different mechanisms from liver regeneration.

Keywor ds: hepatocellular carcinoma,

hepatocyte growth factor,

interleukin 6, transforming growth factor, epidermal growth factor, receptor Ü 八十六年度及以前的一般 國科會專題計畫(不含產學 合作研究計畫)亦可選擇適 用,惟較特殊的計畫如國科 會規劃案等,請先洽得國科 會各學術處同意。

(2)

2

二、緣由與目的

After surgical resection for hepatocellular carcinoma, the high recurrence rate and poor long term survival of patients remains a serious clinical problem. This poor outcome is partly due to remaining, clinically undetectable, microscopic tumor in the liver remnant.

After partial hepatectomy, HGF, IL-6, TNF-a, EGF and TGF-a are key factors responsible for liver regeneration. If there were cancer cells remained in the remnant liver, these same factors may also stimulate the growth of tumor. To examine this possibility, we determined the receptors of above-mentioned growth factors in surgical resected HCC and correlate them with tumor recurrence.

三、結果與討論

  

We have collected 40 surgical resected HCC samples. Proteins and RNA were extract from the non- tumorous (NT) and tumorous (T) part. Western blots were done to detect c-met (HGF receptor), TNF-R1 (TNF-a receptor), IL6R (IL-6 receptor) and EFG receptor. We are unable to detect any signals of receptors in both NT and T part in 9 cases. This probably represents poor samples preservation resulting in protein degradation. All the receptors can be detected in the remaining 32 cases. There are 3 cases with undetectable c-met in tumor part, and one case without IL6R in tumor part . We compute the quantities of receptors by scanning densitometry. No correlation of amount of growth factor receptor was

found between non-tumor and tumor tissue. The amount of receptors in HCC did not relate to tumor size. The recurrence of HCC did not correlate with the amount of receptors in tumor tissue, age, sex, HBsAg, Anti-HCV and presence of liver cirrhosis. However, we found size difference of IL6R between NT and T in 71% cases.

In summary, we find expression of growth factor receptors responsible for liver regeneration in hepatocellular carcinoma. No correlation was found between recurrence and abundance of receptors in tumor. This probably implied that growth of tumor is manly regulated by mechanisms different from that of normal tissue. Another possibility is that recurrent tumors contain different amount of receptors from original tumors. Another factor complicated the interpretation is that recurrence could arise from original dormant tumor not removed by surgery or from newly growing tumor. However the presence of above-mentioned receptors in HCC implied that during liver regeneration, HCC are exposed to the same growth factors as normal hepatocyte, and potentially could be stimulated to grow.

四、計畫成果自評

We found expression of receptors of growth factors related liver regeneration in HCC. Although we did not find correlation between these receptors and recurrence of HCC, there is possibility that growth of HCC could be stimulated by liver regeneration following hepatectomy. We also found

(3)

3

size difference of IL6R between nontumor and tumor tissue. This may imply different response to IL6 signal. Our findings deserve further investigation.

五、參考文獻

1.Role of growth factors and cytokines in hepatic regeneration. FASEB 1995 9:1527-1536.

2.Liver regeneration versus direct hyperplasia. FASEB 1996 10:1118-1129.

3.Growth signals in liver regeneration. 1997 12:44-46.

4.Liver regeneration Science 1997 276: 60-66.

參考文獻

相關文件

切割分裂 模式形成 形態發生 細胞分化 生長...

2.滴加蒸餾水或亞甲藍液製成水埋標本 3.觀察 石細胞 (厚壁細胞)及

In this section we investigate differential equations that are used to model population growth: the law of natural growth, the logistic equation, and several others.... The Law

• 由於細胞代謝、紫外線的電離輻射、不良的生 活習慣 ( 煙、酒、肥胖 ) 、各種感染物所引起 的中性粒細胞、巨噬細胞的激活, 會催化分子 氧發生單價還原產生的 "

SF12144A 張基晟 比較 Nanoplatin 併用 Pemetrexed 和 Cisplatin 併用 Pemetrexed 作為第一線治 療用於非鱗狀細胞性之非小細胞肺癌

If the points line on the 45 o line then the skewness and excess kurtosis seen in the stochastic residuals is the same as that of a standard normal distribution, which indicates

 the lymphocyte function-associated antigen 1, or LFA-1, was so named because antibodies recognizing this structure interfere with lymphocyte cell adhesion events and

SF11310 張基晟 比較 Ipilimumab 加上 Etoposide/Platinum 與 Etoposide/Platinum